Leerink Swann Maintains an 'Outperform' on Pharmasset (VRUS); Checks Indicate Phase IIb Trial of RG7128 is Progressing Well
Tweet Send to a Friend
Leerink Swann maintains an 'Outperform' rating on Pharmasset, Inc. (Nasdaq: VRUS), raises price target from $18 to $27.
Leerink analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
